A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia
Lucy Vivash, Charles B Malpas, Leonid Churilov, Mark Walterfang, Amy Brodtmann, Olivier Piguet, Rebekah M Ahmed, Ashley Bush, Christopher M Hovens, T Kalincik, David Darby, Dennis Velakoulis, Terence J O'Brien
BMJ Open | BMJ PUBLISHING GROUP | Published : 2020
INTRODUCTION: Behavioural variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder often neuropathologically associated with the accumulation of abnormally hyperphosphorylated tau, for which there is currently no disease-modifying treatment. Previous work by our group has shown sodium selenate upregulates the activity of protein phosphatase 2 in the brain, increasing the rate of tau dephosphorylation. The objective of this study is to evaluate the efficacy and safety of sodium selenate as a disease-modifying treatment for bvFTD. METHODS AND ANALYSIS: This will be a multisite, phase IIb, double-blind placebo-controlled trial of sodium selenate. One hundred and twenty participan..View full abstract
Awarded by Australian National Health and Medical Research Council (NHMRC) Medical Research Future Fund
Awarded by NHMRC Senior Research Fellowship
This work is supported by the Australian National Health and Medical Research Council (NHMRC) Medical Research Future Fund grant number APP1170276. OP is supported by an NHMRC Senior Research Fellowship (GNT1103258).